Precise and error-prone CRISPR-directed gene editing activity in human CD34+ cells varies widely among patient samples
Shirin R Modarai, Sambee Kanda, Kevin Bloh, Lynn M Opdenaker, Eric B Kmiec, Shirin R Modarai, Sambee Kanda, Kevin Bloh, Lynn M Opdenaker, Eric B Kmiec
Abstract
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and their associated CRISPR-associated nucleases (Cas) are among the most promising technologies for the treatment of hemoglobinopathies including Sickle Cell Disease (SCD). We are only beginning to identify the molecular variables that influence the specificity and the efficiency of CRISPR- directed gene editing, including the position of the cleavage site and the inherent variability among patient samples selected for CRISPR-directed gene editing. Here, we target the beta globin gene in human CD34+ cells to assess the impact of these two variables and find that both contribute to the global diversity of genetic outcomes. Our study demonstrates a unique genetic profile of indels that is generated based on where along the beta globin gene attempts are made to correct the SCD single base mutation. Interestingly, even within the same patient sample, the location of where along the beta globin gene the DNA is cut, HDR activity varies widely. Our data establish a framework upon which realistic protocols inform strategies for gene editing for SCD overcoming the practical hurdles that often impede clinical success.
Trial registration: ClinicalTrials.gov NCT03745287.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
- Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: an update. Cytotherapy. 2018. 10.1016/j.jcyt.2018.04.003.
- Cavazzana Marina, Antoniani Chiara, Miccio A. Gene therapy for b-hemoglobinopathies. Molecure Ther. 2017;25:1142–54. doi: 10.1016/j.ymthe.2017.03.024.
- Antoniani C, Meneghini V, Lattanzi A, Felix T, Romano O, Magrin E, et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human b-globin locus. Blood. 2018;131:1960–73. doi: 10.1182/blood-2017-10-811505.
- Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014:346. 10.1126/science.1258096.
- Maeder MLGC. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24:430–46. doi: 10.1038/mt.2016.10.
- Cornu TI, Mussolino CCT. Refining strategies to translate genome editing to the clinic. Nat Med. 2017;23:415–23. doi: 10.1038/nm.4313.
- Dewitt MA, Magis W, Bray NL, Urbinati F, Muñoz DP, Kohn DB, et al. Efficient corrections of the sickle mutation in human hematopoietic stem cells using a Cas9 ribonucleoprotein complex. BioRxiv. 2016. Published online January 15, 2016. 10.1101/036236.
- Wen J, Tao W, Hao S, Zu Y. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing. J Hematol Oncol. 2017;10:1–11. doi: 10.1186/s13045-017-0489-9.
- Hirsch ML, Green L, Porteus MH, Samulski R. Self-complementary AAV mediates gene targeting and enhances endonuclease delivery for double-strand break repair. Gene Ther. 2010;17:1175–80. doi: 10.1038/gt.2010.65.
- Rosa Lidonnici, Maria Ferrari G. Gene therapy and gene editing strategies for hemoglobinpathies. Blood Cells Mol Dis. 2018;70:87–101. doi: 10.1016/j.bcmd.2017.12.001.
- Colella Pasqualina, Ronzitti Giuseppe, Mingozzi F. Emerging Issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87–104. doi: 10.1016/j.omtm.2017.11.007.
- Chen F, Pruett-Miller SM, Huang Y, Gjoka M, Duda K, Taunton J, et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods. 2011;8:753–5. doi: 10.1038/nmeth.1653.
- Brown N, Song L, Kollu NR, Hirsch ML. Adeno-associated virus vectors and stem cells: friends or foes? Hum Gene Ther. 2017;28:450–63.
- Bialk P, Sansbury B, Rivera-Torres N, Bloh K, Man D, Kmiec EB. Analyses of point mutation repair and allelic heterogeneity generated by CRISPR/Cas9 and single-stranded DNA oligonucleotides. Sci Rep. 2016;6:1–9. doi: 10.1038/srep32681.
- Modarai SR, Man D, Bialk P, Rivera-Torres N, Bloh K, Kmiec EB. Efficient delivery and nuclear uptake is not sufficient to detect gene editing in CD34+ cells directed by a ribonucleoprotein complex. Mol Ther—Nucleic Acids. 2018;11:116–29. doi: 10.1016/j.omtn.2018.01.013.
- Brinkman EK, Chen T, Amendola M, Van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42. 10.1093/nar/gku936.
- Brinkman EK, Kousholt AN, Harmsen T, Leemans C, Chen T, Jonkers J, et al. Easy quantification of template-directed CRISPR/Cas9 editing. Nucleic Acids Res. 2018:1–9.
- Hoban MD, Lumaquin D, Kuo CY, Romero Z, Long J, Ho M, et al. CRISPR/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol Ther. 2016;24:1561–9. doi: 10.1038/mt.2016.148.
- Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539:384–9. doi: 10.1038/nature20134.
- Allen F, Crepaldi L, Alsinet C, Strong AJ, Kleshchevnikov V, De Angeli P, et al. Predicting the mutations generated by repair of Cas9-induced double-strand breaks. Nat Biotechnol. 2019;37:64–82.. doi: 10.1038/nbt.4317.
- Shen MW, Arbab M, Hsu JY, Worstell D, Culbertson SJ, Krabbe O, et al. Predictable and precise template-free CRISPR editing of pathogenic variants. Nature. 2018;563:646–51. doi: 10.1038/s41586-018-0686-x.
- Carroll D. p53 throws CRISPR a curve. Trends Pharmacol Sci. 2018;39:783–4. doi: 10.1016/j.tips.2018.06.005.
- Foronda M, Dow LE. CRISPR: stressed about p53? Trends Mol Med. 2018;24:731–3. doi: 10.1016/j.molmed.2018.06.010.
- Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24:927–30. doi: 10.1038/s41591-018-0049-z.
- Schiroli G, Conti A, Ferrari S, della Volpe L, Jacob A, Albano L, et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell. 2019;24:551–565.e8. doi: 10.1016/j.stem.2019.02.019.
- Lepik D, Jaks V, Kadaja L, Värv S, Maimets T. Electroporation and carrier DNA cause p53 activation, cell cycle arrest, and apoptosis. Anal Biochem. 2003;318:52–59. doi: 10.1016/S0003-2697(03)00135-0.
- Davis R, Gurumurthy A, Hossain MA, Gunn EM, Bungert J. Engineering globin gene expression. Mol Ther—Methods Clin Dev. 2019;12:102–10. doi: 10.1016/j.omtm.2018.12.004.
- Bak RO, Dever DP, Porteus MH. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc. 2018;13:358–76. doi: 10.1038/nprot.2017.143.
- Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol. 2015;33. 10.1038/nbt.3198.
- Cradick TJ, Fine EJ, Antico CJ, Bao G. CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 2013;41:9584–92. doi: 10.1093/nar/gkt714.
- Alfoldi J, Orkin SH, Tardif J-C, Lessard S, Francioli L, Lettre G, et al. Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci. Proc Natl Acad Sci USA. 2017;114:E11257–66.. doi: 10.1073/pnas.1714640114.
- Park S, Gianotti-Sommer A, Molina-Estevez FJ, Vanuytsel K, Skvir N, Leung A, et al. A comprehensive, ethnically diverse library of sickle cell disease-specific induced pluripotent stem cells. Stem Cell Rep. 2017;8:1076–85. doi: 10.1016/j.stemcr.2016.12.017.
- Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018. 10.1038/nbt.4192.
- Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, et al. P53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24:939–46. doi: 10.1038/s41591-018-0050-6.
- Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062–78. doi: 10.1016/j.cell.2017.08.028.
- Wang Y, Liu KI, Sutrisnoh N-A, Srinivasan H, Zhang J, Li J, et al. Systemic evaluation of CRISPR-Cas systems reveals design principles for genome editing in human cells. Genome Biol. 2018:19. 10.1186/s13059-018-1445.
- Magis W, Dewitt MA, Wyman SK, Vu JT, Heo S, Shirley J, et al. In vivo selection for corrected β-globin alleles after CRISPR/Cas9 editing in human sickle hematopoietic stem cells enhances therapeutic potential. BioRxiv. 2018. Published November 2, 2018. 10.1101/432716.
Source: PubMed